North America Locally Advanced Pancreatic Cancer Market - 2025-2033

The North America locally advanced pancreatic cancer market reached US$ 607.89 million in 2024 and is expected to reach US$ 1,086.35 million by 2033, growing at a CAGR of 6.7 % during the forecast period 2025-2033.

Locally advanced pancreatic cancer refers to a stage of pancreatic cancer where the tumor is confined to the pancreas and the surrounding areas but has not spread to distant organs like the liver, lungs, or distant lymph nodes. In this stage, the cancer has grown locally and may involve nearby blood vessels, nerves, or structures, making it difficult to remove surgically.

The cancer may extend to adjacent structures such as the duodenum, bile ducts, spleen, and large blood vessels (such as the superior mesenteric artery or the portal vein), which can make surgery risky or infeasible. Despite the cancer being confined to the local area, it is often considered "unresectable" at this stage because the tumor's involvement with nearby blood vessels or nerves means complete surgical removal is not possible without risking severe complications.

The management of locally advanced pancreatic cancer usually involves a combination of chemotherapy, radiation therapy, and in some cases, targeted therapy or immunotherapy. Surgery might be an option in rare cases if the tumor shrinks significantly after treatment, allowing it to become resectable.

Market Dynamics: Drivers & Restraints

Rising Demand for Advanced Therapies

The rising demand for advanced therapies is significantly driving the growth of the North America locally advanced pancreatic cancer market by providing patients with more effective treatment options, improving survival rates, and enhancing the overall quality of care. Locally advanced pancreatic cancer is often diagnosed at an advanced stage, and traditional chemotherapy treatments have limitations, prompting the need for innovative therapies that can target the disease more precisely and effectively. It is a general practice to enroll patients in ongoing clinical trials to improve their overall survival.

Several clinical trials are currently ongoing that are evaluating a plethora of treatment options for locally advanced pancreatic cancer, and are showing promising results. For instance, immune checkpoint inhibitors like nivolumab (Opdivo) and pembrolizumab (Keytruda) are being tested for their potential to treat locally advanced pancreatic cancer. These therapies work by boosting the immune system to recognize and attack cancer cells, showing promise in clinical trials for pancreatic cancer. Research suggests that combining immune checkpoint inhibitors with chemotherapy (e.g., FOLFIRINOX) has the potential to improve patient outcomes by enhancing the immune response against the tumor.

Moreover, in December 2024, Novocure announced that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.

The demand for these advanced therapies is growing as they offer the potential for longer overall survival and better quality of life for locally advanced pancreatic cancer patients. Several advanced therapies are currently in clinical development and are showing promising results in the treatment of locally advanced pancreatic cancer.

The rising demand for advanced therapies in the North American LAPC market reflects a broader shift toward personalized, high-precision cancer care. As more innovative treatments prove their clinical value, their integration into standard practice will accelerate market growth, improve patient outcomes, and shape the future of oncology in this space.

Limited Efficacy of Current Therapies

The limited efficacy of current therapies is a significant challenge that hampers the growth of the North America locally advanced pancreatic cancer (LAPC) market. Despite advances in treatment, this type of pancreatic cancer remains one of the most difficult cancers to treat due to its aggressive nature, late-stage diagnosis, and resistance to many therapies.

However, chemotherapy stands as a major therapy option for the condition, whose efficacy is limited in the majority of the patient population, and a recurrence is expected in most of them. For instance, the standard treatment for LAPC often includes FOLFIRINOX, gemcitabine, nab-paclitaxel, etc. While this regimen improves survival compared to monotherapies, it is still only effective for a portion of patients, prolonging the survival rate to a limited extent.

Additionally, immune checkpoint inhibitors, like nivolumab and pembrolizumab, were considered promising, but further trials have to be conducted to evaluate their efficacy and whether they can prolong the overall survival rate as compared with the current therapies.

Segment Analysis

The North America locally advanced pancreatic cancer market is segmented based on therapy and end-user.

Therapy:

The chemotherapy segment in the therapy is expected to dominate the North America locally advanced pancreatic cancer market share

Chemotherapy is a drug treatment that essentially kills cells, especially the fast-growing cancer cells, and inhibits their rapid growth and multiplication. Various chemotherapy drugs could be used either alone or in combination to treat different types of cancers. The most common chemotherapy drugs used in locally advanced pancreatic cancer are Gemcitabine, Folfirinox, Nab-Paclitaxel, Cisplatin, and others.

At present, chemotherapy stands as a major therapeutic option for locally advanced pancreatic cancer, with many health governing bodies recommending it as a first-line treatment option in LAPC. These drugs shrink the tumor size, making it convenient for surgical resection.

As per the National Comprehensive Cancer Network (NCCN) guidelines, the standard of care for LAPC includes FOLFIRINOX or modified FOLFIRINOX, or Gemcitabine + nab-paclitaxel. Chemotherapy is practiced across the world as the first line of care, due to its efficacy as compared to other treatment options, and its capability to improve the overall survival rate in LAPC patients.

Furthermore, key players in the industry focus more on the research activities that would drive this segment's growth in the North America LAPC market. For instance, in August 2024, in California, RenovoRx, Inc. announced the enrollment of the first patient at the University of Nebraska Medical Center (UNMC) in its pivotal Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer (LAPC). The TIGeR-PaC trial is evaluating RenovoRx's novel TAMP (Trans-Arterial Micro-Perfusion) therapy platform, which is designed to deliver chemotherapy directly to the tumor site.

The company's lead candidate, RenovoGem, a drug-device combination, uses pressure-mediated delivery of gemcitabine through the arterial wall to saturate the tumor region. This localized delivery method is being compared against the current standard-of-care, systemic intravenous chemotherapy.

Competitive Landscape

The major players in the North America locally advanced pancreatic cancer market include Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd., Sun Pharmaceutical Industries Ltd., Merus N.V., CHEPLAPHARM Arzneimittel GmbH, and Bayer AG, among others.

Key Developments

• In May 2024, in the U.S., Heriva Biologics, a clinical-stage company focused on developing cancer therapeutics, received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for its lead clinical candidate, VCN-01. This designation applies to VCN-01 when used in combination with gemcitabine and nab-paclitaxel, which are standard chemotherapy drugs, for the treatment of locally advanced and metastatic pancreatic adenocarcinoma.
• In March 2024, Bristol Myers Squibb announced that the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI (adagrasib) as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Bristol has also stated that KRAZAITI has yielded promising benefits in phase II trials for advanced pancreatic cancer.
• In October 2022, ViewRay, Inc. initiated a Phase III clinical trial named "locally advanced pancreatic cancer treated with ABLATivE stereotactic MRI-guided adaptive radiation therapy," or LAP-ABLATE. This trial aims to compare the current standard treatment for locally advanced pancreatic cancer (LAPC), which is multi-agent chemotherapy alone, to a new approach that combines chemotherapy with a specific type of radiation therapy called 5-fraction MRIdian SMART.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The North America locally advanced pancreatic cancer market report delivers a detailed analysis with 36 key tables, more than 23 visually impactful figures, and 136 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.